Late-Breaking Abstract Showcases One-Year Outcomes of Pivotal MRI-Guided Transurethral Ultrasound Ablation of Localized Prostate Tumors

     
     WHEN:  
     Sunday, May 5, 2019, 10:30 a.m.





     
     WHERE:   AUA Press Suite (Field B, Hyatt Regency
                  McCormick Place)





     
     WHAT:    Expert Q&A Opportunity to Discuss the TULSA-PRO
                  Ablation Clinical Trial (TACT)





     
     WHY:     Magnetic-resonance imaging (MRI) is increasing
                  in use in the diagnosis and treatment of
                  prostate cancer. The TACT study, a multi-
                  center trial across institutions in the United
                  States, Canada and Europe, explores the
                  efficacy of MRI-guided transurethral
                  ultrasound ablation technology in men with
                  localized disease and presents one-year
                  outcomes from TACT.




                 The study will be presented publicly at on May 5
                  during the Plenary: Next Frontier session.





     
     WHO:     Study author Dr. Scott Eggener, Professor of
                  Surgery and Radiology at the University of
                  Chicago, will share data and take questions
                  from interested members of the press.

About the American Urological Association: Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has more than 22,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health policy.

Contact:
Wendy Isett, AUA
443-845-4031, wisett@AUAnet.org

/PRNewswire -- May 5, 2019/

SOURCE American Urological Association